Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia
Clinical trial NCT03798509 · UNKNOWN
Trial details
- NCT number
- NCT03798509
- Sponsor
- Hrain Biotechnology Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-13
- Primary completion
- 2022-01-01
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.